比较相位分辨功能肺(PREFUL)与超极化129Xe MRI对儿童囊性纤维化患者接受elexacaftor/tezacaftor/ivacaftor治疗后肺功能的纵向监测
本研究对14例囊性纤维化儿童在ETI治疗前及治疗后1、6、12、24个月行PREFUL MRI、超极化129Xe MRI和肺功能检查,发现PREFUL各指标在治疗后1个月显著改善,与Xe-MRI和肺功能变化一致;VDPCC和VDPcombined的绝对变化与VDPXe显著相关,而VDPRVent和QDP变化与VDPXe无显著相关。
要点
- PREFUL MRI可在ETI治疗后1个月检出肺通气灌注改善,与超极化129Xe MRI及肺功能检查结果一致。
- VDPCC和VDPcombined的绝对变化与VDPXe显著相关(r≥0.62,P<0.02),VDPRVent变化与VDPXe无显著相关(P=0.35)。
- QDP变化与任何指标均无显著相关(P>0.10)。
核心结论
- PREFUL MRI可检测囊性纤维化儿童ETI治疗后肺通气和灌注的纵向治疗相关变化。
研究设计与样本
- 纵向比较研究,纳入14例囊性纤维化患者(中位[IQR]年龄15[14-16.5]岁),在ETI治疗前及治疗后1、6、12、24个月行PREFUL MRI、超极化129Xe MRI和肺功能检查;采用Wilcoxon符号秩检验评估1个月治疗变化,采用Spearman秩相关分析指标间相关性。
诊断标准与关键数值
- PREFUL MRI衍生指标包括区域通气VDP(VDPRVent)、区域血流容积环互相关VDP(VDPCC)及两者组合VDP(VDPcombined);Xe-MRI衍生VDPXe;灌注缺损百分比(QDP)由归一化灌注图衍生,与VDPcombined共同确定健康通气-灌注匹配百分比(VQM)。治疗后1个月所有PREFUL指标显著改善(P<0.01),与Xe-MRI VDP和肺功能检查变化一致(P<0.03)。VDPCC和VDPcombined绝对变化与VDPXe显著相关(r≥0.62,P<0.02),VDPRVent与VDPXe无显著相关(P=0.35)。QDP变化与任何指标均无显著相关(P>0.10)。治疗后1至24个月PREFUL MRI和Xe-MRI指标变化极小(中位变化=-2.3%至1.4%),与肺功能检查一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Phase-resolved functional lung (PREFUL) MRI offers a more accessible alternative to hyperpolarized 129Xe MRI (Xe-MRI) for monitoring treatment response in pediatric cystic fibrosis (CF), but longitudinal comparisons are limited.
OBJECTIVE: To assess longitudinal lung function changes following elexacaftor/tezacaftor/ivacaftor (ETI) treatment initiation in CF children using PREFUL MRI, in comparison with Xe-MRI and pulmonary function tests (PFTs).
MATERIALS AND METHODS: PREFUL MRI, Xe-MRI, and PFTs were performed in 14 CF patients (median [IQR] age 15 [14-16.5] years old) at baseline and 1 month, 6 months, 12 months, and 24 months following initiation of ETI treatment. Ventilation and defect percentage (VDP) was derived from PREFUL MRI (regional ventilation VDP, VDPRVent; regional-flow volume loop cross-correlation VDP, VDPCC; and the combination of VDPRVent and VDPCC, VDPcombined) and Xe-MRI (VDPXe) maps. Perfusion defect percentage (QDP) was derived from normalized perfusion maps and, with VDPcombined, determined the percentage of healthy ventilation-perfusion matching (VQM). Significance of 1-month treatment changes was determined using the Wilcoxon-signed rank test and was correlated between metrics using Spearman ranked correlation.
RESULTS: All PREFUL measures significantly improved (P < 0.01) 1-month post-treatment in agreement with changes in Xe-MRI VDP and PFTs (P < 0.03). The absolute change in VDPCC and VDPcombined significantly correlated with VDPXe (r ≥ 0.62, P < 0.02), unlike VDPRVent (P = 0.35). The change in QDP did not correlate with any metric (P > 0.10). PREFUL MRI and Xe-MRI measures showed minimal changes 1 to 24 months post-treatment (median changes = -2.3% to 1.4%), in agreement with PFTs.
CONCLUSION: PREFUL MRI detects longitudinal treatment-related changes in pulmonary ventilation and perfusion in CF children post ETI.
引用
- Munidasa S, Alam F, Zanette B, et al. Comparison of phase-resolved functional lung (PREFUL) and hyperpolarized 129Xe MRI for longitudinal monitoring of lung function in pediatric cystic fibrosis following elexacaftor/tezacaftor/ivacaftor. Pediatr Radiol. 2025. PMID: 40938435. doi:10.1007/s00247-025-06390-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。